Akeso Printed Ivonescimab plus Ligufalimab as First-Line Therapy for PD-L1-Optimistic Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024 By Investing.com
Head-to-Head Section 3 Trial In comparison with Pembrolizumab Initiated HONG KONG, Sept.…
Research outcomes from section 1 research with exidavnemab printed in The Journal of Medical Pharmacology By Investing.com
STOCKHOLM, Aug. 27, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA…
Eurofins Supplies Replace to Key Stakeholders on Present and Upcoming Actions Following Communications Revealed by Muddy Waters Since 24 June 2024 By Investing.com
LUXEMBOURG--(BUSINESS WIRE)--Regulatory Information: Eurofins (Paris:ERF): As has been performed in earlier press…
